Cutaneous vasculitis associated with gemcitabine therapy

Coadministration of 5% glucose solution relieves vascular pain in the patients administered gemcitabine immediately

“…Some causes of the vascular toxicity of gemcitabine have been reported thrombotic microangiopathy, venoocclusive disease, and digital ischemic changes and necrosis. 8,[14][15][16][17] However, the exact mechanism regarding this is unknown, although it is suggested to be more common and more severe after cumulative doses of 10,000 mg/m 2 or in the setting of combination therapy. 13 Moreover, regarding the risk factors that may potentiate the vascular pain from gemcitabine administration, there is a possibility that one of them may be distal ischemic changes related to organic vascular disease due to hypercholesterolemia, arterial hypertension, or exposure to tobacco.…”

Acute generalized exanthematous pustulosis caused by gemcitabine

“…Common among them are nonspecific rash, radiation recall dermatitis, scleroderma-like changes, erysipeloid skin lesions, pseudolymphoma, linear immunoglobulin A bullous dermatosis, and leukocytoclastic vasculitis. 6 Other more rarely reported side effects include digital ischemia and necrosis, 7 and Stevens-Johnson syndrome/toxic epidermal necrosis. 8 To our knowledge, ours is the first report of AGEP induced by gemcitabine.…”

Gemcitabine therapy‐associated cutaneous vasculitis with a polyarteritis nodosa‐like pattern

“…Cutaneous vasculitis due to gemcitabine therapy has only recently been reported by Corella et al. 5 in a 79‐year‐old man who developed cutaneous small vessel leukocytoclastic vasculitis. Although there are several reports of systemic vascular toxicity in patients with gemcitabine treatment, 6 we could not find previously reported cases of necrotizing vasculitis with a PAN‐like pattern.…”